A multi-strain Synbiotic may reduce viral respiratory infections in asthmatic children: a randomized controlled trial
Background and objective: Asthma is a growing problem worldwide. Acute exacerbations impose considerable morbidity, mortality, and increased cost. Viral respiratory infections are the most common cause (80-85%) of pediatric asthma exacerbations and admissions to the hospital. The aim of this study...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Electronic Physician
2016-09-01
|
| Series: | Electronic Physician |
| Subjects: | |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074739/ |
| _version_ | 1818390626077507584 |
|---|---|
| author | Hamid Ahanchian Seyed Ali Jafari Elham Ansari Toktam Ganji Mohammad Ali Kiani Maryam Khalesi Tooba Momen Hamidreza Kianifar |
| author_facet | Hamid Ahanchian Seyed Ali Jafari Elham Ansari Toktam Ganji Mohammad Ali Kiani Maryam Khalesi Tooba Momen Hamidreza Kianifar |
| author_sort | Hamid Ahanchian |
| collection | DOAJ |
| description | Background and objective: Asthma is a growing problem worldwide. Acute exacerbations impose considerable
morbidity, mortality, and increased cost. Viral respiratory infections are the most common cause (80-85%) of
pediatric asthma exacerbations and admissions to the hospital. The aim of this study was to determine the effect
of a new synbiotic Lactocare® on viral respiratory infections and asthma exacerbations in asthmatic children.
Methods: In this double blind, placebo-controlled, randomized clinical trial, 72 children with mild persistent
asthma, aged between 6 and 12 years, were randomized to receive either Lactocare®, a Synbiotic containing 1
billion CFU/Capsule of Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus thermophilus,
Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium infantis, Lactobacillus bulgaricus, and
Fructooligosacharide (Zist Takhmir, Tehran, Iran) or placebo daily for 60 days. The primary outcome was the
number of viral respiratory infections, and secondary outcomes were school absence, salbutamol and
prednisolone usage, outpatient visits, and hospital admission for asthma. The outcomes were compared among
study groups using the SPSS 11.5 program and the Mann Whitney and Fisher exact tests.
Results: Of the 72 children who were enrolled with mild persistent asthma, 36 were assigned randomly to be
treated with synbiotic and 36 with placebo. The number of viral respiratory infections was significantly higher in
placebo group than the synbiotic group during the first month of intervention (0.74 ± 0.12 vs. 0.44 ± 0.1, p <
0.007) but not during the second month (0.5 ± 0.8 vs. 0.5 ± 0.8, p < 0.641). Considering the total duration of the
study (two months), infection episodes also were significantly lower in the synbiotic group (0.92 ± 0.15 vs. 0.69
± 0.11, p < 0.046). Salbutamol consumption was significantly lower in the synbiotic group, but there were no
significant differences in school absenteeism, oral prednisolone use, outpatient visits, or hospital admissions.
Conclusion: This new synbiotic (a mixture of seven probiotic strains plus fructooligosacharide may reduce
episodes of viral infection in asthmatic children.
Trial registration: This study is registered in Iranian Registry of Clinical Trials with registration number of
IRCT201509234976N3. Funding: This research was supported financially by the Research Council of Mashhad University of Medical
Sciences (Grant Number: 911048). |
| first_indexed | 2024-12-14T05:00:37Z |
| format | Article |
| id | doaj.art-f9cb56e1df884488b01b987e3f24662b |
| institution | Directory Open Access Journal |
| issn | 2008-5842 2008-5842 |
| language | English |
| last_indexed | 2024-12-14T05:00:37Z |
| publishDate | 2016-09-01 |
| publisher | Electronic Physician |
| record_format | Article |
| series | Electronic Physician |
| spelling | doaj.art-f9cb56e1df884488b01b987e3f24662b2022-12-21T23:16:15ZengElectronic PhysicianElectronic Physician2008-58422008-58422016-09-01892833283910.19082/2833A multi-strain Synbiotic may reduce viral respiratory infections in asthmatic children: a randomized controlled trialHamid AhanchianSeyed Ali JafariElham AnsariToktam GanjiMohammad Ali KianiMaryam KhalesiTooba MomenHamidreza KianifarBackground and objective: Asthma is a growing problem worldwide. Acute exacerbations impose considerable morbidity, mortality, and increased cost. Viral respiratory infections are the most common cause (80-85%) of pediatric asthma exacerbations and admissions to the hospital. The aim of this study was to determine the effect of a new synbiotic Lactocare® on viral respiratory infections and asthma exacerbations in asthmatic children. Methods: In this double blind, placebo-controlled, randomized clinical trial, 72 children with mild persistent asthma, aged between 6 and 12 years, were randomized to receive either Lactocare®, a Synbiotic containing 1 billion CFU/Capsule of Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium infantis, Lactobacillus bulgaricus, and Fructooligosacharide (Zist Takhmir, Tehran, Iran) or placebo daily for 60 days. The primary outcome was the number of viral respiratory infections, and secondary outcomes were school absence, salbutamol and prednisolone usage, outpatient visits, and hospital admission for asthma. The outcomes were compared among study groups using the SPSS 11.5 program and the Mann Whitney and Fisher exact tests. Results: Of the 72 children who were enrolled with mild persistent asthma, 36 were assigned randomly to be treated with synbiotic and 36 with placebo. The number of viral respiratory infections was significantly higher in placebo group than the synbiotic group during the first month of intervention (0.74 ± 0.12 vs. 0.44 ± 0.1, p < 0.007) but not during the second month (0.5 ± 0.8 vs. 0.5 ± 0.8, p < 0.641). Considering the total duration of the study (two months), infection episodes also were significantly lower in the synbiotic group (0.92 ± 0.15 vs. 0.69 ± 0.11, p < 0.046). Salbutamol consumption was significantly lower in the synbiotic group, but there were no significant differences in school absenteeism, oral prednisolone use, outpatient visits, or hospital admissions. Conclusion: This new synbiotic (a mixture of seven probiotic strains plus fructooligosacharide may reduce episodes of viral infection in asthmatic children. Trial registration: This study is registered in Iranian Registry of Clinical Trials with registration number of IRCT201509234976N3. Funding: This research was supported financially by the Research Council of Mashhad University of Medical Sciences (Grant Number: 911048).https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074739/AsthmaChildrenProbioticSynbioticViral infection |
| spellingShingle | Hamid Ahanchian Seyed Ali Jafari Elham Ansari Toktam Ganji Mohammad Ali Kiani Maryam Khalesi Tooba Momen Hamidreza Kianifar A multi-strain Synbiotic may reduce viral respiratory infections in asthmatic children: a randomized controlled trial Electronic Physician Asthma Children Probiotic Synbiotic Viral infection |
| title | A multi-strain Synbiotic may reduce viral respiratory infections in asthmatic children: a randomized controlled trial |
| title_full | A multi-strain Synbiotic may reduce viral respiratory infections in asthmatic children: a randomized controlled trial |
| title_fullStr | A multi-strain Synbiotic may reduce viral respiratory infections in asthmatic children: a randomized controlled trial |
| title_full_unstemmed | A multi-strain Synbiotic may reduce viral respiratory infections in asthmatic children: a randomized controlled trial |
| title_short | A multi-strain Synbiotic may reduce viral respiratory infections in asthmatic children: a randomized controlled trial |
| title_sort | multi strain synbiotic may reduce viral respiratory infections in asthmatic children a randomized controlled trial |
| topic | Asthma Children Probiotic Synbiotic Viral infection |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074739/ |
| work_keys_str_mv | AT hamidahanchian amultistrainsynbioticmayreduceviralrespiratoryinfectionsinasthmaticchildrenarandomizedcontrolledtrial AT seyedalijafari amultistrainsynbioticmayreduceviralrespiratoryinfectionsinasthmaticchildrenarandomizedcontrolledtrial AT elhamansari amultistrainsynbioticmayreduceviralrespiratoryinfectionsinasthmaticchildrenarandomizedcontrolledtrial AT toktamganji amultistrainsynbioticmayreduceviralrespiratoryinfectionsinasthmaticchildrenarandomizedcontrolledtrial AT mohammadalikiani amultistrainsynbioticmayreduceviralrespiratoryinfectionsinasthmaticchildrenarandomizedcontrolledtrial AT maryamkhalesi amultistrainsynbioticmayreduceviralrespiratoryinfectionsinasthmaticchildrenarandomizedcontrolledtrial AT toobamomen amultistrainsynbioticmayreduceviralrespiratoryinfectionsinasthmaticchildrenarandomizedcontrolledtrial AT hamidrezakianifar amultistrainsynbioticmayreduceviralrespiratoryinfectionsinasthmaticchildrenarandomizedcontrolledtrial AT hamidahanchian multistrainsynbioticmayreduceviralrespiratoryinfectionsinasthmaticchildrenarandomizedcontrolledtrial AT seyedalijafari multistrainsynbioticmayreduceviralrespiratoryinfectionsinasthmaticchildrenarandomizedcontrolledtrial AT elhamansari multistrainsynbioticmayreduceviralrespiratoryinfectionsinasthmaticchildrenarandomizedcontrolledtrial AT toktamganji multistrainsynbioticmayreduceviralrespiratoryinfectionsinasthmaticchildrenarandomizedcontrolledtrial AT mohammadalikiani multistrainsynbioticmayreduceviralrespiratoryinfectionsinasthmaticchildrenarandomizedcontrolledtrial AT maryamkhalesi multistrainsynbioticmayreduceviralrespiratoryinfectionsinasthmaticchildrenarandomizedcontrolledtrial AT toobamomen multistrainsynbioticmayreduceviralrespiratoryinfectionsinasthmaticchildrenarandomizedcontrolledtrial AT hamidrezakianifar multistrainsynbioticmayreduceviralrespiratoryinfectionsinasthmaticchildrenarandomizedcontrolledtrial |